(Q37405307)

20 August 2017

1 reference

title

Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action (English)

1 reference

20 August 2017

1

Siegfried Kasper

0 references

author name string

Michel Hamon

series ordinal

2

1 reference

20 August 2017

publication date

1 January 2009

1 reference

World Journal of Biological Psychiatry

20 August 2017

published in

1 reference

20 August 2017

volume

10

1 reference

20 August 2017

issue

2

1 reference

20 August 2017

page(s)

117-126

1 reference

Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS).

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

New selective ligands of human cloned melatonin MT1 and MT2 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Drug treatment of depression in the 2000s: An overview of achievements in the last 10 years and future possibilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Antidepressant action of agomelatine (S 20098) in a transgenic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

The pineal gland and melatonin: molecular and pharmacologic regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Role of melatonin in the regulation of human circadian rhythms and sleep

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Clinical efficacy of agomelatine in depression: the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Melatonin and its new agonist S-20098 restore synchronized sleep fragmented by experimental trypanosome infection in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Differential effects of the novel antidepressant agomelatine (S 20098) versus fluoxetine on 5-HT1A receptors in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Neurogenesis and depression: etiology or epiphenomenon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Nocturnal TSH and prolactin secretion during sleep deprivation and prediction of antidepressant response in patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Depressed new neurons--adult hippocampal neurogenesis and a cellular plasticity hypothesis of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Placebo-controlled trial of agomelatine in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Distinct mechanism for antidepressant activity by blockade of central substance P receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Sleep disturbances and depression: a challenge for antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

The selective neurokinin (NK)(1) antagonist, GR205,171, stereospecifically enhances mesocortical dopaminergic transmission in the rat: a combined dialysis and electrophysiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Selective blockade of neurokinin (NK)(1) receptors facilitates the activity of adrenergic pathways projecting to frontal cortex and dorsal hippocampus in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Animal models of depressive illness: the importance of chronic drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Outcomes in major depressive disorder: the evolving concept of remission and its implications for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Why do we need new and better antidepressants?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Is severe depression a separate indication? ECNP Consensus Meeting September 20, 1996, Amsterdam. European College of Neuropsychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Sleep disturbances and psychiatric disorders associated with posttraumatic stress disorder in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Effect of agomelatine in the chronic mild stress model of depression in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Entrainment of rat circadian rhythms by the melatonin agonist S-20098 requires intact suprachiasmatic nuclei but not the pineal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Antiglucocorticoid drugs in the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Use of melatonin for sleep and circadian rhythm disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Comparative effects of a melatonin agonist on the circadian system in mice and Syrian hamsters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Chronic mild stress-induced anhedonia: a realistic animal model of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Antidepressants and sleep: a qualitative review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Novel naphthalenic ligands with high affinity for the melatonin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Agomelatine: a preliminary review of a new antidepressant

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Differences in nocturnal melatonin secretion between melancholic depressed patients and control subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Circadian rhythm mechanisms in affective illness and in antidepressant drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

Actigraphy in Patients with Seasonal Affective Disorder and Healthy Control Subjects Treated with Light Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970902717024

10.1080/15622970902717024

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference